$35M+ for Kolltan Pharma


Yale University Medical School spinoff Kolltan Pharmaceuticals of New Haven, CT, announced that it has closed a Series A financing round worth over $35 million. Kolltan is developing cancer treatments based on the work of Yale’s Joseph Schlessinger, a cofounder and director of the startup and its chief scientist. The company also named Michael Schmertzler as its CEO.

By posting a comment, you agree to our terms and conditions.